Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.

Ann Rheum Dis

Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA

Published: July 2022

Download full-text PDF	Source
http://dx.doi.org/10.1136/annrheumdis-2022-222115	DOI Listing

Publication Analysis

neutralisation circulating

circulating sars-cov-2

sars-cov-2 delta

delta omicron

omicron variants

variants convalescent

convalescent plasma

plasma sars-cov-2

sars-cov-2 hyperimmune

hyperimmune intravenous

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!